XTLBNasdaqPharmaceutical Preparations

XTL BIOPHARMACEUTICALS LTD

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 30, 2026

$1.96−0.00 (-0.01%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

XTL BIOPHARMACEUTICALS LTD income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31
Revenue	–	0.45	–	–	–	–	–	–	–	–	–
Cost of Revenue	–	0.45	–	–	–	–	–	–	–	–	–
Gross Profit	–	0.00	–	–	–	–	–	–	–	–	–
Research & Development	0.03	0.02	0.03	0.03	0.03	0.04	0.04	0.04	0.04	0.44	0.58
Selling, General & Admin	–	–	0.73	0.85	1.00	–	–	–	–	–	–
Selling & Marketing	–	0.49	–	–	–	–	–	–	–	–	–
General & Administrative	–	–	–	–	–	0.91	0.81	0.76	–	–	–
Operating Income	-1.69	-0.78	-0.77	-0.88	-1.03	-0.95	-0.84	-0.79	-1.25	-2.56	-3.61
Interest Expense	0.27	0.11	1.06	1.56	0.02	2.19	0.60	0.04	0.34	0.01	0.02
Interest & Investment Income	1.20	1.13	0.04	1.09	1.49	0.18	0.68	3.81	0.80	0.02	0.00
Pretax Income	-0.76	0.24	-1.78	-1.35	–	–	–	–	–	–	–
Income Tax Expense	–	-0.13	–	–	–	–	–	–	–	–	–
Income from Continuing Operations	-0.76	0.24	-1.78	–	–	–	–	–	-0.78	-2.55	-3.62
Income from Discontinued Operations	-6.21	-1.27	–	–	–	–	–	–	–	–	-0.69
Net Income incl. Noncontrolling Interests	-6.97	-1.03	-1.78	-1.35	0.44	-2.95	-0.76	3.63	-0.78	-2.55	-4.31
Minority Interest in Earnings	–	–	–	–	–	–	-1.35	2.99	-0.78	-2.55	-4.31
Net Income	–	–	–	–	–	–	–	–	–	–	0.00
EPS (Basic)(per share)	-0.0080	-0.0020	-0.0030	-0.0020	0.0010	-0.0060	-0.0010	0.0060	-0.0020	-0.0090	-0.02
EPS (Diluted)(per share)	-0.0080	-0.0020	-0.0030	-0.0020	0.00	-0.0060	-0.0010	0.0060	-0.0020	-0.0090	-0.02
Shares Outstanding (Basic, Weighted)(shares)	896	673	545	545	532	514	514	514	470	274	264
Shares Outstanding (Diluted, Weighted)(shares)	896	673	545	545	616	514	514	514	470	274	264
EBITDA	–	–	–	–	–	–	–	–	-1.25	-2.56	-3.60

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: –
Debt to equity: –
Debt to assets: –
Cash to current liabilities: –

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –